Expression and intracellular localization of FKHRL1 in mammary gland neoplasms

Gui Shan Jin, Eisaku Kondo, Takayoshi Miyake, Masao Shibata, Takako Takashima, Yi Xuan Liu, Kazuhiko Hayashi, Tadaatsu Akagi, Tadashi Yoshino

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

FKHRL1 (FOXO3a), a member of the Forkhead family of genes, has been considered to be involved in the development of breast tumors; however, the in vivo expression and activation status of FKHRL1 in breast tumors still remains unclear. We immunohistochemically demonstrated the expression and intracellular localization of FKHRL1 in human breast tumors by the novel anti-FKHRL1 antibody which is available for formalin-fixed paraffin-embedded specimens. In a total of 51 cases of benign tumors, FKHRL1 was diffusely expressed in all cases, and its intracellular localization was revealed to be cytoplasmic (inactive form) in 94% of cases of intraductal papillomas (16/17) and 91% cases of fibroadenomas (31/34), with a similar pattern to normal glandular epithelium. In invasive ductal carcinomas, 83% of the cases (93/112) diffusely expressed FKHRL1; however, unlike benign tumors, 71% of the cases (66/93) showed the nuclear-targeted, active form of FKHRL1. Moreover, activated FKHRL1 was predominantly observed in scirrhous (29/36, 81% of the cases) and papillotubular (30/38, 79% of the cases) subtypes, compared to the solid-tubular subtype (7/19, 37% of the cases). Furthermore, the cases with nuclear-targeted FKHRL1 showed a tendency to have lymph nodal metastasis with statistical significance (P <0.0001). Thus, the activation of FKHRL1 seems to be recognized as one of the specific features of invasive ductal carcinoma of the breast.

Original languageEnglish
Pages (from-to)197-205
Number of pages9
JournalActa Medica Okayama
Volume58
Issue number4
Publication statusPublished - Aug 2004

Fingerprint

Animal Mammary Neoplasms
Tumors
Breast Neoplasms
Intraductal Papilloma
Carcinoma, Ductal, Breast
Fibroadenoma
Ductal Carcinoma
Lymph
Paraffin
Formaldehyde
Chemical activation
Anti-Idiotypic Antibodies
Neoplasms
Epithelium
Neoplasm Metastasis
Genes
Antibodies

Keywords

  • Breast tumors
  • FKHRL1
  • Intracellular localization

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Jin, G. S., Kondo, E., Miyake, T., Shibata, M., Takashima, T., Liu, Y. X., ... Yoshino, T. (2004). Expression and intracellular localization of FKHRL1 in mammary gland neoplasms. Acta Medica Okayama, 58(4), 197-205.

Expression and intracellular localization of FKHRL1 in mammary gland neoplasms. / Jin, Gui Shan; Kondo, Eisaku; Miyake, Takayoshi; Shibata, Masao; Takashima, Takako; Liu, Yi Xuan; Hayashi, Kazuhiko; Akagi, Tadaatsu; Yoshino, Tadashi.

In: Acta Medica Okayama, Vol. 58, No. 4, 08.2004, p. 197-205.

Research output: Contribution to journalArticle

Jin, GS, Kondo, E, Miyake, T, Shibata, M, Takashima, T, Liu, YX, Hayashi, K, Akagi, T & Yoshino, T 2004, 'Expression and intracellular localization of FKHRL1 in mammary gland neoplasms', Acta Medica Okayama, vol. 58, no. 4, pp. 197-205.
Jin GS, Kondo E, Miyake T, Shibata M, Takashima T, Liu YX et al. Expression and intracellular localization of FKHRL1 in mammary gland neoplasms. Acta Medica Okayama. 2004 Aug;58(4):197-205.
Jin, Gui Shan ; Kondo, Eisaku ; Miyake, Takayoshi ; Shibata, Masao ; Takashima, Takako ; Liu, Yi Xuan ; Hayashi, Kazuhiko ; Akagi, Tadaatsu ; Yoshino, Tadashi. / Expression and intracellular localization of FKHRL1 in mammary gland neoplasms. In: Acta Medica Okayama. 2004 ; Vol. 58, No. 4. pp. 197-205.
@article{f4031eda6ab043c2a460fbc6616deb34,
title = "Expression and intracellular localization of FKHRL1 in mammary gland neoplasms",
abstract = "FKHRL1 (FOXO3a), a member of the Forkhead family of genes, has been considered to be involved in the development of breast tumors; however, the in vivo expression and activation status of FKHRL1 in breast tumors still remains unclear. We immunohistochemically demonstrated the expression and intracellular localization of FKHRL1 in human breast tumors by the novel anti-FKHRL1 antibody which is available for formalin-fixed paraffin-embedded specimens. In a total of 51 cases of benign tumors, FKHRL1 was diffusely expressed in all cases, and its intracellular localization was revealed to be cytoplasmic (inactive form) in 94{\%} of cases of intraductal papillomas (16/17) and 91{\%} cases of fibroadenomas (31/34), with a similar pattern to normal glandular epithelium. In invasive ductal carcinomas, 83{\%} of the cases (93/112) diffusely expressed FKHRL1; however, unlike benign tumors, 71{\%} of the cases (66/93) showed the nuclear-targeted, active form of FKHRL1. Moreover, activated FKHRL1 was predominantly observed in scirrhous (29/36, 81{\%} of the cases) and papillotubular (30/38, 79{\%} of the cases) subtypes, compared to the solid-tubular subtype (7/19, 37{\%} of the cases). Furthermore, the cases with nuclear-targeted FKHRL1 showed a tendency to have lymph nodal metastasis with statistical significance (P <0.0001). Thus, the activation of FKHRL1 seems to be recognized as one of the specific features of invasive ductal carcinoma of the breast.",
keywords = "Breast tumors, FKHRL1, Intracellular localization",
author = "Jin, {Gui Shan} and Eisaku Kondo and Takayoshi Miyake and Masao Shibata and Takako Takashima and Liu, {Yi Xuan} and Kazuhiko Hayashi and Tadaatsu Akagi and Tadashi Yoshino",
year = "2004",
month = "8",
language = "English",
volume = "58",
pages = "197--205",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - Expression and intracellular localization of FKHRL1 in mammary gland neoplasms

AU - Jin, Gui Shan

AU - Kondo, Eisaku

AU - Miyake, Takayoshi

AU - Shibata, Masao

AU - Takashima, Takako

AU - Liu, Yi Xuan

AU - Hayashi, Kazuhiko

AU - Akagi, Tadaatsu

AU - Yoshino, Tadashi

PY - 2004/8

Y1 - 2004/8

N2 - FKHRL1 (FOXO3a), a member of the Forkhead family of genes, has been considered to be involved in the development of breast tumors; however, the in vivo expression and activation status of FKHRL1 in breast tumors still remains unclear. We immunohistochemically demonstrated the expression and intracellular localization of FKHRL1 in human breast tumors by the novel anti-FKHRL1 antibody which is available for formalin-fixed paraffin-embedded specimens. In a total of 51 cases of benign tumors, FKHRL1 was diffusely expressed in all cases, and its intracellular localization was revealed to be cytoplasmic (inactive form) in 94% of cases of intraductal papillomas (16/17) and 91% cases of fibroadenomas (31/34), with a similar pattern to normal glandular epithelium. In invasive ductal carcinomas, 83% of the cases (93/112) diffusely expressed FKHRL1; however, unlike benign tumors, 71% of the cases (66/93) showed the nuclear-targeted, active form of FKHRL1. Moreover, activated FKHRL1 was predominantly observed in scirrhous (29/36, 81% of the cases) and papillotubular (30/38, 79% of the cases) subtypes, compared to the solid-tubular subtype (7/19, 37% of the cases). Furthermore, the cases with nuclear-targeted FKHRL1 showed a tendency to have lymph nodal metastasis with statistical significance (P <0.0001). Thus, the activation of FKHRL1 seems to be recognized as one of the specific features of invasive ductal carcinoma of the breast.

AB - FKHRL1 (FOXO3a), a member of the Forkhead family of genes, has been considered to be involved in the development of breast tumors; however, the in vivo expression and activation status of FKHRL1 in breast tumors still remains unclear. We immunohistochemically demonstrated the expression and intracellular localization of FKHRL1 in human breast tumors by the novel anti-FKHRL1 antibody which is available for formalin-fixed paraffin-embedded specimens. In a total of 51 cases of benign tumors, FKHRL1 was diffusely expressed in all cases, and its intracellular localization was revealed to be cytoplasmic (inactive form) in 94% of cases of intraductal papillomas (16/17) and 91% cases of fibroadenomas (31/34), with a similar pattern to normal glandular epithelium. In invasive ductal carcinomas, 83% of the cases (93/112) diffusely expressed FKHRL1; however, unlike benign tumors, 71% of the cases (66/93) showed the nuclear-targeted, active form of FKHRL1. Moreover, activated FKHRL1 was predominantly observed in scirrhous (29/36, 81% of the cases) and papillotubular (30/38, 79% of the cases) subtypes, compared to the solid-tubular subtype (7/19, 37% of the cases). Furthermore, the cases with nuclear-targeted FKHRL1 showed a tendency to have lymph nodal metastasis with statistical significance (P <0.0001). Thus, the activation of FKHRL1 seems to be recognized as one of the specific features of invasive ductal carcinoma of the breast.

KW - Breast tumors

KW - FKHRL1

KW - Intracellular localization

UR - http://www.scopus.com/inward/record.url?scp=4644354580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644354580&partnerID=8YFLogxK

M3 - Article

VL - 58

SP - 197

EP - 205

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -